Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Amyotrophic Lateral Sclerosis (ALS) Clinical Trials

A listing of Amyotrophic Lateral Sclerosis (ALS) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (11) clinical trials

AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the mitochondria and endoplasmic reticulum (ER). This clinical trial is designed to demonstrate that treatment is safe, tolerable, and able to slow decline in function as measured by the ALSFRS-R. The ...

Phase

The purpose of this study is to assess the effect of CK-2127107 versus placebo on respiratory function and other measures of skeletal muscle function in patients with ALS.

Phase

Cistanche Total Glycosides for Amyotrophic Lateral Sclerosis: A Randomized Control Trial (RCT) Study Assessing Clinical Response

This study will examine the effectiveness of Cistanche Total Glycosides(CTG) in treating patients with amyotrophic lateral sclerosis (ALS) - a fatal neurological degenerative disease that causes adult-onset, progressive motor neurons loss in the spinal cord, brain stem and motor cortex. Patients develop progressive wasting and weakness of both upper and ...

Phase

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

One of the major disease features of ALS is the progressive death of motor neurons. Human, rodent and stem cell-based model studies support the hypothesis that neuronal hyperexcitability may contribute to neurodegeneration in both sporadic and familial ALS. The investigators are doing this research study to find out whether retigabine ...

Phase

Safety and Biomarker Study of EPI-589 in Subjects With ALS

Open label with 30-day run in phase to establish baseline parameters and a 90-day withdrawal phase to determine duration of treatment response.

Phase

A Trial of Tocilizumab in ALS Subjects

This is a multicenter, randomized, double-blind, placebo-controlled 16-week study evaluating the safety and tolerability of tocilizumab in subjects with sporadic ALS. The primary objective of the study is to determine the safety and tolerability of intravenous administration of 8 mg/kg of tocilizumab every 4 weeks vs. matched intravenous placebo administered ...

Phase

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

This is a randomized, double-blind, placebo-controlled study of NP001 in subjects with ALS and evidence of elevated systemic inflammation. Subjects will be allocated (1:1) to NP001 and placebo. Drug or placebo will be given intravenously.

Phase

Efficacy and Safety of Plasma Exchange With Albutein 5% in Patients With Amyotrophic Lateral Sclerosis

This is a phase IIa, prospective, open-label, single-arm pilot study to evaluate the efficacy and safety of PE with Albutein® 5% in subjects with ALS. The planned enrollment is 10 subjects who have a definite, possible, or probable diagnosis of ALS, according to the revised El Escorial criteria. Enrolled subjects ...

Phase

A Study to Assess the Efficacy and Safety of H.P. Acthar Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis

This is a multicenter, multiple dose study to examine the effect of Acthar on functional decline in adult subjects with amyotrophic lateral sclerosis (ALS). Approximately 213 subjects will be enrolled. Following a screening period of up to 28 days, subjects with ALS and symptom onset (defined as first muscle weakness ...

Phase

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the mitochondria and endoplasmic reticulum (ER). This clinical trial is designed to demonstrate that treatment is safe, tolerable, and able to slow decline in function as measured by the ALSFRS-R. The ...

Phase